银杏注射剂治疗冠心病心绞痛的疗效和安全性的网状 Meta 分析和系统评价。
Efficacy and safety of ginkgo injections in the treatment of angina pectoris caused by coronary heart disease in China: a network Meta-analysis and systematic review.
机构信息
Department of Clinical Pharmacology of Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, China.
China Academy of Chinese Medical Sciences, Beijing 100700, China.
出版信息
J Tradit Chin Med. 2019 Jun;39(3):285-296.
OBJECTIVE
To assess the clinical efficacy and safety of ginkgo injections (GIs) combined with conventional treatment (CT) against angina pectoris (AP) due to coronary heart disease (CHD).
METHODS
Randomized controlled trials (RCTs) that used GIs to treat AP were searched in SinoMed, PubMed, China National Knowledge Infrastructure Database, Chinese Scientific Journals Database, Wanfang Database, Embase and Cochrane Library until March 2017. The Cochrane"risk of bias"method was used to evaluate the methodological quality of RCTs. Data were analyzed using Stata v13.1 and WinBUGS v1.4.3.
RESULTS
A total of 73 RCTs involving 7621 patients were included. A Bayesian network Meta-analysis of RCTs was undertaken, and the advantages of four types of GI-supplemented CT in AP treatment were determined.
CONCLUSION
GI-assisted CT was more effective against AP than CT alone. However, based on the limitations of the study, additional high-quality RCTs are required to confirm our findings.
目的
评估银杏注射液（GIs）联合常规治疗（CT）治疗冠心病心绞痛（AP）的临床疗效和安全性。
方法
检索中国生物医学文献数据库、PubMed、中国知网、中文科技期刊数据库、万方数据库、Embase 和 Cochrane 图书馆，搜集截至 2017 年 3 月银杏制剂治疗 AP 的随机对照试验（RCT）。采用 Cochrane“偏倚风险”评估方法评价 RCT 方法学质量，采用 Stata v13.1 和 WinBUGS v1.4.3 进行贝叶斯网状 Meta 分析。
结果
共纳入 73 项 RCT，涉及 7621 例患者。网状 Meta 分析结果显示，4 种银杏制剂联合 CT 治疗 AP 均优于 CT 单药治疗。
结论
银杏制剂联合 CT 治疗 AP 优于 CT 单药治疗，但受纳入研究质量限制，尚需开展更多高质量 RCT 加以验证。
Zotero 插件